NCT00075478 - Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

February 28, 2014

Study Completion Date

February 2, 2014

Conditions

Acute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia in RemissionAggressive Non-Hodgkin LymphomaChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDiffuse Large B-Cell LymphomaHematopoietic and Lymphoid Cell NeoplasmIndolent Non-Hodgkin LymphomaMantle Cell LymphomaMyelodysplastic/Myeloproliferative NeoplasmPlasma Cell MyelomaRefractory Chronic Lymphocytic LeukemiaRefractory Hodgkin LymphomaWaldenstrom Macroglobulinemia

Interventions

PROCEDURE

Total-Body Irradiation

Undergo TBI

DRUG

Fludarabine Phosphate

Given IV

DRUG

Mycophenolate Mofetil

Given PO

DRUG

Cyclosporine

Given PO

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo transplantation

Trial Locations (10)

10126

University of Torino, Torino

50924

Medizinische Univ Klinik Koln, Cologne

53226

Froedtert and the Medical College of Wisconsin, Milwaukee

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

84143

LDS Hospital, Salt Lake City

97504

OHSU Cancer Institute-Southern Region, Medford

98101

VA Puget Sound Health Care System, Seattle

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

D-04103

Universitaet Leipzig, Leipzig

D-72076

University of Tuebingen-Germany, Tübingen

All Listed Sponsors

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER